Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
20
BIO Quote, Financials, Valuation and Earnings
Last price:
$256.80
Seasonality move
:
9.37%
Day range:
$251.00 - $272.79
52-week range:
$211.43 - $343.12
Dividend yield:
0%
P/E ratio:
9.19x
P/S ratio:
2.71x
P/B ratio:
1.03x
Volume:
1.1M
Avg. volume:
267.3K
1-year change:
-16.26%
Market cap:
$6.9B
Revenue:
$2.6B
EPS (TTM):
$27.91
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $328.00, Bio-Rad Laboratories, Inc. has an estimated upside of 27.85% from its current price of $256.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $280.00 representing -9.14% downside risk from its current price of $256.56.
Fair Value
-
According to the consensus of 5 analysts, Bio-Rad Laboratories, Inc. has 27.85% upside to fair value with a price target of $328.00 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories, Inc. has underperformed the S&P 500 by -13.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Bio-Rad Laboratories, Inc. reported revenues of $693.2M.
Earnings Growth
-
Bio-Rad Laboratories, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Rad Laboratories, Inc. reported earnings per share of $26.65.
Enterprise value:
6.6B
EV / Invested capital:
0.76x
Price / LTM sales:
2.71x
EV / EBIT:
24.83x
EV / Revenue:
2.55x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
12.38x
Price / Operating cash flow:
13.15x
Enterprise value / EBITDA:
13.99x
Gross Profit (TTM):
$1.3B
Return On Assets:
7.7%
Net Income Margin (TTM):
29.42%
Return On Equity:
10.99%
Return On Invested Capital:
9.2%
Operating Margin:
9.02%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $2.7B | $2.6B | $2.6B | $667.5M | $693.2M | |
| Gross Profit | $1.4B | $1.4B | $1.3B | $355.1M | $344.8M | |
| Operating Income | $385M | $331.5M | $265.3M | $84.8M | $62.5M | |
| EBITDA | $589.3M | $524.3M | $470.7M | $134.1M | $114.9M | |
| Diluted EPS | -$21.50 | -$65.04 | $27.91 | -$25.57 | $26.65 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2B | $3.2B | $3B | $3B | $2.9B | |
| Total Assets | $17.8B | $13.5B | $12.3B | $9.4B | $10.6B | |
| Current Liabilities | $680.9M | $568.7M | $522.8M | $467.8M | $517M | |
| Total Liabilities | $4.1B | $3.9B | $3.6B | $2.8B | $3.1B | |
| Total Equity | $13.7B | $9.6B | $8.7B | $6.6B | $7.5B | |
| Total Debt | $197.9M | $1.4B | $1.4B | $1.3B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $374.9M | $454.6M | $532.2M | $124.2M | $164.9M | |
| Cash From Investing | $20.2M | -$160.2M | -$189.7M | -$30.5M | -$34.2M | |
| Cash From Financing | -$425.6M | -$218.2M | -$283.2M | -$26.3M | $3.3M | |
| Free Cash Flow | $218.3M | $289M | $532.2M | $81.3M | $164.9M | |
BIO
Sector
Market Cap
$6.9B
$24M
Price % of 52-Week High
74.77%
48.29%
Dividend Yield
0%
0%
Shareholder Yield
3.92%
-1.62%
1-Year Price Total Return
-16.26%
-22.92%
Beta (5-Year)
1.180
0.500
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$293.06
200-day SMA
Sell
Level
$282.04
Bollinger Bands (100)
Sell
Level
293.17 - 322.69
Chaikin Money Flow
Buy
Level
36.7M
20-day SMA
Sell
Level
$298.29
Relative Strength Index (RSI14)
Sell
Level
23.54
ADX Line
Sell
Level
20.13
Williams %R
Buy
Level
-91.0912
50-day SMA
Sell
Level
$306.37
MACD (12, 26)
Sell
Level
-7.16
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
25.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7964)
Buy
CA Score
(Annual)
Level (0.6914)
Sell
Beneish M-Score
(Annual)
Level (-2.1497)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-4.5207)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $328.00.
-
Where Will Bio-Rad Laboratories, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories, Inc. share price will rise to $328.00 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories, Inc.?
Analysts are divided on their view about Bio-Rad Laboratories, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories, Inc. is a Sell and believe this share price will drop from its current level to $280.00.
-
What Is Bio-Rad Laboratories, Inc.'s Price Target?
The price target for Bio-Rad Laboratories, Inc. over the next 1-year time period is forecast to be $328.00 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories, Inc. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories, Inc. shares.
-
What Is The Bio-Rad Laboratories, Inc. Share Price Today?
Bio-Rad Laboratories, Inc. was last trading at $256.80 per share. This represents the most recent stock quote for Bio-Rad Laboratories, Inc.. Yesterday, Bio-Rad Laboratories, Inc. closed at $256.56 per share.
-
How To Buy Bio-Rad Laboratories, Inc. Stock Online?
In order to purchase Bio-Rad Laboratories, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BIO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIO
Sector
P/E ratio
9.19x
23.44x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.03x
1.73x
Price / LTM sales
2.71x
1.51x
Growth Metrics
BIO
Sector
Revenue growth
3.85%
3.31%
Earnings growth
204.24%
10.7%
Revenue (5-year growth)
0.29%
6.28%
Earnings forecast
$2.70
-$0.19
Profitability
BIO
Sector
Profitability FY 2025
$1.3B
$2.6M
Return on invested capital
9.2%
-33.62%
Return on assets
7.7%
-29.74%
Return on equity
10.99%
-39.33%
Earnings Date
Last Earnings Date
Feb
12
Next Earnings Date
Apr
30
Estimated Next Earnings Date
May
14
Balance Sheet
BIO
Sector
Total cash
$1.5B
$25M
Short term investments
$1.2B
$23.9M
Total assets
$10.6B
$71.9M
Long term debt
$1.2B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
